Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients

Blood

Volumn 120, Issue 12, 2012, Pages 2405-2411

  Santagostino, Elena ^a   Negrier, Claude ^b   Klamroth, Robert ^c   Tiede, Andreas ^d   Pabinger Fasching, Ingrid ^e   Voigt, Christine ^f   Jacobs, Iris ^f   Morfini, Massimo ^g  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITÉ LYON 1   (France)

^c VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f CSL BEHRING   (United States)

^g CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR 9; HYBRID PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; HEMOPHILIA B; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 84866594053     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-429688     Document Type: Article

References (23)

1. Mannucci PM, Tuddenham EGD. The hemophilias: from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773-1779.
2. Pergantou H, Matsinos G, Papadopoulos A, Platokouki H, Aronis S. Comparative study of validity of clinical, X-ray and magnetic resonance imaging scores in evaluation and management of haemophilic arthropathy in children. Haemophilia. 2006;12(3):241-247.
3. Kim HC, McMillan CW, White GC, et al. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood. 1992;79(3):568-575.
4. Roth DA, Kessler CM, Pasi KJ, et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood. 2001;98(13):3600-3606.
5. National Hemophilia Foundation. MASAC Recommendation #179: Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). New York, NY: National Hemophilia Foundation; 2007.
6. Astermark J, Petrini P, Tengborn L, et al. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol. 1999;105(4):1109-1113.
7. BeneFIX (coagulation Factor IX Recombinant). Summary of Product Characteristics for BeneFIX, Electronic Medicines Compendium, 2010. https://www.medicines.org.uk/emc/medicine/20376/SPC/BeneFIX/#PHARMACODINAMIC- PROPS. Accessed July14, 2012.
8. De Moerloose P, Urbancik W, van den Berg HM, Richards M. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemophilia. 2008;14(5):931-938.
9. Santagostino E, Mancuso ME. Venous access in haemophilic children: choice and management. Haemophilia. 2010;16(Suppl 1):20-24.
10. Negrier C, Knobe K, Tiede A, Giangrande P, Moss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood. 2012;118(10):2695-2701.
11. Shapiro AD, Ragni MV, Valentino LA, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood. 2012;119(3):666-672.
12. Schulte S. Half-life extension through albumin fusion technologies. Thromb Res. 2009;124(Suppl 2):S6-S8.
13. Metzner HJ, Weimer T, Kronthaler U, et al. Genetic fusion to albumin improves the pharmacokinetic properties of Factor IX. Thromb Haemost. 2009;102(4):634-644.
14. Chaubal M. Human serum albumin as a pharmaceutical excipient. Drug Deliv Technol. 2005;5(8).
15. Duttaroy A, Kanakaraj P, Osborn BL, et al. Development of a long-acting insulin analog using albumin fusion technology. Diabetes. 2005;54(1):251-258.
16. Syed S, Schuyler PD, Kulczycky M, Sheffield WP. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood. 1997;89(9):3243-3252.
17. Zeuzem S, Sulkowski MS, Lawitz EJ, et al. Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology. 2010;139(4):1257-1266.
18. European Medicines Evaluation Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline in the Clinical Investigation of Recombinant and Human Plasma-Derived Factor IX Products. CHMP/BPWP/144552/2009. London, United Kingdom: European Medicines Evaluation Agency; 2009.
19. Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX: Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb Haemost. 1991;66(3):384-386.
20. Lee M, Morfini M, Schulman S, et al. Scientific and Standardization Committee Communication: The Design and Analysis of Pharmacokinetic Studies of Coagulation Factors, 2001. http://isth.org/default/assets/File/fviiipharmaco. pdf. Accessed August 20, 2012.
21. Warrier I, Ewenstein BM, Koerper M, et al. Factor IX inhibitors and anaphylaxis in hemophilia B. Am J Pediatr Hematol Oncol. 1997;19(1):23-27.
22. Collins PW, Fischer K, Morfini M, et al. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia. 2011;17(1):2-10.
23. Ahnström J, Berntorp E, Lindvall K, Björkman. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004;10(6):689-697.